<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9137">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704556</url>
  </required_header>
  <id_info>
    <org_study_id>VX22-548-014</org_study_id>
    <nct_id>NCT05704556</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics and Safety of VX 548 in Participants With Renal Impairment</brief_title>
  <official_title>A Phase 1, Open-label Study to Evaluate the Pharmacokinetics and Safety of Single Doses of VX-548 in Subjects With Severe or Moderate Renal Impairment and in Matched Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability&#xD;
      of VX-548 and its metabolite in participants with severe or moderate renal impairment and&#xD;
      healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial information was submitted voluntarily under the applicable law and,&#xD;
      therefore, certain submission deadlines may not apply. (That is, clinical trial information&#xD;
      for this applicable clinical trial was submitted under section 402(j)(4) (A) of the Public&#xD;
      Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by&#xD;
      sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2023</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of VX-548 and its Metabolite</measure>
    <time_frame>Day 1 to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-548 and its Metabolite</measure>
    <time_frame>Day 1 to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of VX-548</measure>
    <time_frame>Day 1 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Renal Clearance of VX-548 and its Metabolite (CLr)</measure>
    <time_frame>Day 1 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Non-Renal Clearance of VX-548</measure>
    <time_frame>Day 1 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 to Day 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction Unbound (fu) for VX-548 and its Metabolite in Plasma</measure>
    <time_frame>Day 1 to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound Area Under the Concentration Versus Time Curve of VX-548 and its Metabolite</measure>
    <time_frame>Day 1 to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of VX-548 in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Matched Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants matched to cohort 1 will receive a single doses of VX-548 in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of VX-548 in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Matched Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants matched to cohort 3 will receive a single dose of VX-548 in a fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-548</intervention_name>
    <description>Tablets for oral administration.</description>
    <arm_group_label>Cohort 1: Severe Renal Impairment</arm_group_label>
    <arm_group_label>Cohort 2: Matched Healthy Participants</arm_group_label>
    <arm_group_label>Cohort 3: Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Cohort 4: Matched Healthy Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Cohorts 1 and 3: Participants with Severe or Moderate Renal Impairment&#xD;
&#xD;
               -  Body mass index (BMI) of greater than or equal to (&gt;=)18.0 to less than (&lt;) 40.0&#xD;
                  kilogram per square meter (kg/m^2)&#xD;
&#xD;
               -  Stable renal function for at least 1 month prior to enrollment, as assessed by&#xD;
                  the site investigator&#xD;
&#xD;
          -  Cohorts 2 and 4: Matched Healthy Participants&#xD;
&#xD;
               -  Healthy participants will be matched to Cohorts 1 and 3 participants according to&#xD;
                  each of the following parameters: sex, age (±10 years), and BMI (±15%)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Cohorts 1 and 3: Participants with Severe or Moderate Renal Impairment&#xD;
&#xD;
               -  Hemoglobin less than or equal to (≤) 9.0 gram per deciliter (g/dL) at screening&#xD;
&#xD;
          -  Cohorts 2 and 4: Matched Healthy Participants&#xD;
&#xD;
               -  Prior renal transplantation, prior hemodialysis, or prior peritoneal dialysis&#xD;
&#xD;
          -  All Cohorts:&#xD;
&#xD;
               -  History of febrile or acute illness that has not fully resolved by 14 days before&#xD;
                  study drug dosing.&#xD;
&#xD;
               -  Any condition possibly affecting drug absorption&#xD;
&#xD;
        Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GCP Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Genesis Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 19, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>June 5, 2023</last_update_submitted>
  <last_update_submitted_qc>June 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

